• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ARWR

    Arrowhead Pharmaceuticals Inc.

    Subscribe to $ARWR
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

    IPO Year:

    Exchange: NASDAQ

    Website: arrowheadpharma.com

    Recent Analyst Ratings for Arrowhead Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    6/5/2024$31.00Neutral
    Goldman
    12/4/2023$29.00Buy
    BofA Securities
    9/19/2023$33.00Neutral
    Citigroup
    7/21/2023Outperform
    TD Cowen
    5/12/2023$40.00Outperform → Market Perform
    SVB Securities
    4/26/2023$80.00Outperform
    SMBC Nikko
    4/12/2023$21.00 → $35.00Market Perform → Outperform
    SVB Securities
    3/21/2023$27.00Mkt Perform
    Bernstein
    9/9/2022$41.00Equal-Weight
    Morgan Stanley
    5/11/2022$71.00 → $60.00Neutral → Outperform
    Robert W. Baird
    See more ratings

    Arrowhead Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

    - Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash - Sarepta's remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to A

    8/13/25 4:10:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

    - Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025

    8/7/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

    - Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China - Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with elevated triglycerides Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of A

    8/1/25 6:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

    - Milestone earned upon reaching first enrollment target in a Phase 1/2 study of ARO-DM1 for the treatment of type 1 myotonic dystrophy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. Arrowhead currently expects to achieve the second enrollment

    7/28/25 7:30:00 AM ET
    $ARWR
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the Company, on July 22, 2025, the Company's Board of Directors approved "inducement" grants to 38 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 52,680 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest annually over four years. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient

    7/24/25 4:30:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaboration Agreement with Sarepta Therapeutics. Arrowhead continues to conduct clinical and non-clinical studies as stipulated in the agreement, and it expects Sarepta to continue to meet its required financial obligations. Sarepta has provided no indication of any intention to fail to fulfill any of its obligations, however if that occurs there are clear termination provisions that would cause assets and associated intellectual property to be returned to Arrowhead. Arrowhead believes its strong balance sheet and multiple opportunities for addi

    7/23/25 8:00:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI3955ca6732974874b0bc0ac323811a7f. Once registered, you w

    7/21/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

    - Zodasiran targets ANGPLT3, an emerging therapeutic target to treat HoFH and other dyslipidemias - YOSEMITE Phase 3 study further enhances Arrowhead's late-stage pipeline of RNAi-based cardiometabolic candidates Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational RNAi-based candida

    7/8/25 7:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

    - Study completion anticipated in mid-2026 with subsequent data readout and regulatory submissions for treatment of severe hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously s

    6/23/25 7:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

    ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissue Study initiation highlights Arrowhead's leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform In preclinical studies, ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company'

    6/2/25 7:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Hamilton James C sold $200,000 worth of shares (10,000 units at $20.00), decreasing direct ownership by 4% to 262,122 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    8/15/25 5:59:02 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Apel Daniel Joseph claimed ownership of 101,200 shares (SEC Form 3)

    3 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    8/12/25 5:49:57 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Anzalone Christopher Richard sold $1,533,337 worth of shares (141,122 units at $10.87), decreasing direct ownership by 3% to 3,921,255 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    4/11/25 6:20:07 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Anzalone Christopher Richard was granted 340,000 shares and sold $774,975 worth of shares (51,425 units at $15.07), increasing direct ownership by 8% to 4,062,377 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    3/17/25 5:45:33 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Anzalone Christopher Richard sold $5,274,334 worth of shares (300,000 units at $17.58) and exercised 300,000 shares at a strike of $7.75 (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    3/5/25 6:32:06 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Anzalone Christopher Richard was granted 9,550 shares, increasing direct ownership by 0.25% to 3,773,802 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    2/10/25 6:23:16 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ingram Douglas S was granted 38,396 shares (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    2/7/25 5:57:52 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Ingram Douglas S claimed no ownership of stock in the company (SEC Form 3)

    3 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    2/7/25 5:57:13 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Olukotun Adeoye Y sold $20,139 worth of shares (959 units at $21.00), decreasing direct ownership by 3% to 35,781 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    1/27/25 7:22:57 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Discovery/Trans Medicine Hamilton James C was granted 100,000 shares and sold $648,824 worth of shares (32,729 units at $19.82), increasing direct ownership by 33% to 272,122 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    1/7/25 9:28:17 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13D/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/15/25 5:28:19 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/14/25 7:07:30 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arrowhead Pharmaceuticals Inc.

    144 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/13/25 8:55:11 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/11/25 7:01:49 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

    8/7/25 4:07:19 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Arrowhead Pharmaceuticals Inc.

    10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

    8/7/25 4:04:44 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    7/29/25 11:20:42 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    5/13/25 10:26:33 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

    5/12/25 4:10:03 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Arrowhead Pharmaceuticals Inc.

    10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

    5/12/25 4:07:46 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Arrowhead with a new price target

    Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00

    6/5/24 7:11:50 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Arrowhead with a new price target

    BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00

    12/4/23 7:19:37 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Arrowhead with a new price target

    Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00

    9/19/23 7:26:13 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Arrowhead

    TD Cowen initiated coverage of Arrowhead with a rating of Outperform

    7/21/23 7:11:47 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead downgraded by SVB Securities with a new price target

    SVB Securities downgraded Arrowhead from Outperform to Market Perform and set a new price target of $40.00

    5/12/23 7:12:21 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SMBC Nikko initiated coverage on Arrowhead with a new price target

    SMBC Nikko initiated coverage of Arrowhead with a rating of Outperform and set a new price target of $80.00

    4/26/23 8:56:08 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead upgraded by SVB Securities with a new price target

    SVB Securities upgraded Arrowhead from Market Perform to Outperform and set a new price target of $35.00 from $21.00 previously

    4/12/23 7:10:43 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Arrowhead with a new price target

    Bernstein initiated coverage of Arrowhead with a rating of Mkt Perform and set a new price target of $27.00

    3/21/23 7:14:02 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Arrowhead with a new price target

    Morgan Stanley initiated coverage of Arrowhead with a rating of Equal-Weight and set a new price target of $41.00

    9/9/22 7:14:54 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Arrowhead from Neutral to Outperform and set a new price target of $60.00 from $71.00 previously

    5/11/22 6:11:04 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    3/20/24 7:06:58 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    View All

    Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

    4/15/25 4:00:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

    NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

    1/22/25 5:54:00 PM ET
    $APO
    $ARWR
    $B
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

    4/16/24 9:00:00 AM ET
    $ANNX
    $ARWR
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022. Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead said, "Vicki is a senior executive with an impressive track record of leading organizations to successfully commercialize important medicines." "I've watched Arrowhead aggressively grow its pipeline and expand the reach of its RNAi technology over the years," said Ms. Vakiener. "I am excited to join the Board now to help contribute to its next phase of growth as Arrowhead takes the

    5/2/22 7:31:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer

    PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer. Dr. Bradshaw is a proven drug developer in the field of precision genetic medicines, coming to NeuBase from his most recent role as Chief Scientific Officer at Arrowhead Pharmaceuticals. In his new role, Dr. Bradshaw will be responsible for leading and expanding NeuBase’s PATrOL-enabled anti-gene pipeline and will serve as a key member of its executive management team. “

    12/2/20 8:00:00 AM ET
    $PFE
    $ABT
    $NBSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

    SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    11/14/24 9:38:25 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    10/16/24 9:15:20 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    4/10/24 2:03:52 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    2/13/24 4:58:53 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    1/24/24 12:57:06 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    6/9/23 2:15:39 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    2/9/23 11:07:44 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    2/8/23 10:08:12 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    2/9/22 3:24:51 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    2/10/21 10:30:33 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Inc. Financials

    Live finance-specific insights

    View All

    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

    - Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash - Sarepta's remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to A

    8/13/25 4:10:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

    - Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025

    8/7/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI3955ca6732974874b0bc0ac323811a7f. Once registered, you w

    7/21/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

    - Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards our long-term goal of developing and ultimately commercializing new innovative medicines for millions of patients. We are on schedule to launch plozasiran this year, pending regulatory approval, with what we think is a best-in-class profile with meaningful differentiation from current

    5/12/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI06c63c27dc8a4e368d2a8316c4143218. Once registered, you will

    4/30/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

    - Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. "During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "The company is now well positioned for

    2/10/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI10095fd77113444788810d4774d5fae3. Once registered, you will

    1/22/25 4:00:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

    - Conference Call and Webcast Today, November 26, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. "Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM™ technology. We have the potential to impact the lives of millions of patients in need. We believe we now have all the necessary pieces in place to drive significant value for shareholders in the short-term, mid-term, and, mor

    11/26/24 4:00:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

    – Sarepta obtains exclusive worldwide licenses to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including potential best-in-class siRNA-based treatments for DM1 and FSHD – Additionally, Arrowhead and Sarepta have entered into a discovery partnership pursuant to which Sarepta will nominate, and Arrowhead will deliver, IND-ready constructs for six targets across skeletal muscle, cardiac, and CNS – Investigational treatments leverage Arrowhead's leading Targeted RNAi Molecule (TRiMTM) platform, capable of deep and durable target-gene knockdown – Upon closing, Arrowhead to receive $500 million in an upfront paymen

    11/26/24 7:00:00 AM ET
    $ARWR
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

    - Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years - Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales - Sarepta to receive investigational treatments that leverage Arrowhead's leading Targeted RNAi Molecule platform - Arrowhead to discuss this agreement during the company's 2024 fiscal year end results conference call today, November 26, 2024, at 4:30 p.m. ET Ar

    11/26/24 7:00:00 AM ET
    $ARWR
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care